Picture of Tandem Diabetes Care logo

TNDM — Tandem Diabetes Care News Story

0.000.00%
us flag iconLast trade - 00:00
HealthcareAdventurousMid CapNeutral

Tandem Diabetes Care Q2 revenue slightly misses estimates

Tandem Diabetes Care Q2 revenue slightly misses estimates


Overview

  • Diabetes technology firm's Q2 revenue grew 6% but slightly missed analyst expectations

  • Gross margin rose to 57% from 52% a year earlier

  • Company narrowed net and operating losses from prior year


Outlook

  • Tandem Diabetes Care sees 2026 sales of $1.065 bln to $1.085 bln

  • Company expects 2026 gross margin of 56% to 57% of sales

  • Company expects 2026 adjusted EBITDA margin of 5% to 6% of sales


Result Drivers

  • PUMP SHIPMENTS - Co reported worldwide pump shipments of more than 33,000, including 22,000 in the U.S.

  • GROSS MARGIN IMPROVEMENT - Gross margin rose to 57%, up 460 basis points from Q2 2025

  • PAY-AS-YOU-GO MODEL - 10% of U.S. sales were through the pharmacy channel due to scaled pay-as-you-go reimbursement


Company press release: ID:nBwKjfVGa


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q2 Sales

Slight Miss*

$254.56 mln

$254.98 mln (20 Analysts)

Q2 Loss Per Share

$0.31

Q2 Net Loss

$21.20 mln

Q2 Gross Margin

57.00%

Q2 Operating income

-$13.80 mln

*Applies to a deviation of less than 1%; not applicable for per-share numbers.


Analyst Coverage

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 12 "strong buy" or "buy", 10 "hold" and no "sell" or "strong sell"

  • The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

  • Wall Street's median 12-month price target for Tandem Diabetes Care, Inc. is $28.00, about 42.9% above its August 5 closing price of $19.59


Reuters Recommended Reads

  • Aug 5 - Insulet cuts sales growth forecast on slower US insulin-pump sales; shares fall

  • Aug 5 - LifeMD Q2 revenue misses estimates as shift to branded GLP-1 therapies weighs

  • Aug 5 - Lilly beats estimates on resilient demand for injectable GLP-1 drugs, widens gap with Novo


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Recent news on Tandem Diabetes Care

See all news